IMNM (Immunome) Institutional Ownership: 108.35% (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IMNM Immunome Inc IMNM
44 GF Score
Price $22.16
GF Value $1.68
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Immunome Institutional Ownership?

Immunome IMNM -0.65% 44 Institutional Ownership is 108.35% as of Jul. 20, 2026. GuruFocus rates IMNM with a GF Score™ of 44/100 and a GF Value™ of $1.68 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Immunome's institutional ownership is 108.35%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Immunome's Insider Ownership is 3.13%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Immunome's Float Percentage Of Total Shares Outstanding is 85.48%.

Immunome Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Immunome's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunome Institutional Ownership Chart

Immunome Historical Data

The historical data trend for Immunome can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 60.06 61.28 63.82 67.59 67.63 68.47 76.50 76.90 76.56 77.86
IMNM
44GF Score
Immunome Inc IMNM
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immunome Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 108.35% mean?
Immunome (IMNM) has a Institutional Ownership of 108.35% as of Jul. 20, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Immunome and its competitors.
Is Immunome's Institutional Ownership too high?
Immunome's current Institutional Ownership is 108.35%. Overall, Immunome has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immunome's Institutional Ownership compare to AGIO and ABCL?
Immunome's Institutional Ownership of 108.35% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Immunome and its competitors. Immunome's current Institutional Ownership is 108.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunome stock overvalued right now?
Based on GuruFocus' analysis, Immunome (IMNM) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.68, compared to a current price of $22.16 — trading 1219% above its estimated fair value. The current Institutional Ownership is 108.35%. Immunome's overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Immunome (IMNM), the current Institutional Ownership is 108.35% as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Immunome (IMNM) Overvalued in 2026?

Based on GuruFocus' analysis, Immunome stock appears to be overvalued. The current stock price of $22.16 is trading 1219% above its estimated GF Value™ of $1.68. GuruFocus considers Immunome to be Significantly Overvalued.

Key valuation signals for IMNM:

  • Institutional Ownership: 108.35%
  • GF Value™: $1.68 vs. price of $22.16 (1219% above fair value)
  • GF Score™: 44/100 with 2 warning signs

No single metric tells the full story. See the IMNM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immunome Business Description

Address 18702 N. Creek Parkway, Suite 100, Bothell, WA, USA, 98011
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
44GF Score

Get the complete analysis for IMNM

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.16
Price
$1.68
GF Value